Literature DB >> 12075402

The expression of EGFR family ligands in breast carcinomas.

Zhenhe Suo1, Bjørn Risberg, Mats G Karlsson, Kenneth Villman, Eva Skovlund, Jahn M Nesland.   

Abstract

Expression of EGF, HB-EGF, TGF-alpha, HRG-alpha, HRG-beta1, and HRG-beta3 in 100 frozen breast carcinoma materials was immunohistochemically studied. Among these tumors, 67% were positive for EGF, 53% for HB-EGF, 57% for TGF-alpha, 60% for HRG-alpha, 53% for HRG-beta1, and 63% for HRG-beta3 in the neoplastic epithelial cells. No significant associations between expression of the growth factors and clinicopathological features like tumor size, histologic grade, node status, ploidy, ER status, and c-erbB-4 expression were observed, with the exceptions that significant relations were present between EGF expression and tumor size (p = 0.01) and between HRG-beta3 expression and node status (p = 0.02). The expressions of these growth factors showed no association with cancer-specific survival by the Kaplan Meier analysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075402     DOI: 10.1177/106689690201000202

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  11 in total

Review 1.  EGFR signaling in breast cancer: bad to the bone.

Authors:  John Foley; Nicole K Nickerson; Seungyoon Nam; Kah Tan Allen; Jennifer L Gilmore; Kenneth P Nephew; David J Riese
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

2.  Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.

Authors:  Suguru Dateoka; Yuichi Ohnishi; Kenji Kakudo
Journal:  Med Mol Morphol       Date:  2012-06-21       Impact factor: 2.309

3.  Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent.

Authors:  Datta E Ponde; ZiFen Su; Alan Berezov; Hongtao Zhang; Abbas Alavi; Mark I Greene; Ramachandran Murali
Journal:  Bioorg Med Chem Lett       Date:  2011-02-15       Impact factor: 2.823

4.  Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.

Authors:  Cynthia Lopez-Haber; Laura Barrio-Real; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Cell Biol       Date:  2016-07-14       Impact factor: 4.272

5.  Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells.

Authors:  Jennifer L Gilmore; Jeffrey A Scott; Zhor Bouizar; Alex Robling; Sarah E Pitfield; David J Riese; John Foley
Journal:  Breast Cancer Res Treat       Date:  2007-09-20       Impact factor: 4.872

6.  TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.

Authors:  K Di; M E Linskey; D A Bota
Journal:  Oncogene       Date:  2012-11-26       Impact factor: 9.867

7.  Ridle for sparse regression with mandatory covariates with application to the genetic assessment of histologic grades of breast cancer.

Authors:  Jing Zhai; Chiu-Hsieh Hsu; Z John Daye
Journal:  BMC Med Res Methodol       Date:  2017-01-25       Impact factor: 4.615

8.  Identification of the cancer cell proliferation and survival functions of proHB-EGF by using an anti-HB-EGF antibody.

Authors:  Shuji Sato; Hiroko Kamada; Takahiro Watanabe; Isamu Tsuji; Jinhong Fan
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240

9.  Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator.

Authors:  Philip Vlaicu; Philipp Mertins; Thomas Mayr; Peter Widschwendter; Beyhan Ataseven; Bernhard Högel; Wolfgang Eiermann; Pjotr Knyazev; Axel Ullrich
Journal:  BMC Cancer       Date:  2013-04-18       Impact factor: 4.430

10.  Progression of luminal breast tumors is promoted by ménage à trois between the inflammatory cytokine TNFα and the hormonal and growth-supporting arms of the tumor microenvironment.

Authors:  Polina Weitzenfeld; Nurit Meron; Tal Leibovich-Rivkin; Tsipi Meshel; Adit Ben-Baruch
Journal:  Mediators Inflamm       Date:  2013-12-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.